E-ISSN 2587-0831
Original Article
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients
1 Department of Pathology, Mardin State Hospital, Mardin, Turkey  
2 Department of Pathology, University of Health Sciences, Şisli Hamidiye Etfal Training and Research Center, İstanbul, Turkey  
3 Department of General Surgery, University of Health Sciences, Şisli Hamidiye Etfal Training and Research Center, İstanbul, Turkey  
Eur J Breast Health 2019; 15: 235-241
DOI: 10.5152/ejbh.2019.4912
Key Words: PD-L1, breast cancer, triple-negative breast cancers, immunohistochemistry, monoclonal antibody
Abstract

 

Objective: Triple-negative breast cancer (TNBC) is a heterogenous group of tumors with no estrogen receptor (ER), progesterone receptor (PR) and Cerb-B2/HER2 expression. Programmed death ligand-1 (PD-L1) is a transmembrane protein located on both non-tumor and tumor cells and it has been shown to be associated with the escape of tumor cells from the immune system. PD-L1-targeted therapy alone or in combination is now an alternative strategy in several aggressive tumor types. In this respect, TNBC is a potential candidate having limited treatment options and poor outcome.

 

Material and Methods: Sixty-one breast cancers with no expression of ER, PR and Cerb-B2/HER2 were chosen to study PD-L1 immunohistochemistry. PD-L1 staining and its correlation with main clinicopathological parameters were evaluated.

 

Results: The percentage of PD-L1 positivity was 37.7% and 47.5% in tumor and tumor microenvironment, respectively. The positivity rate was higher in breast carcinomas with medullary features (83.3%) and metaplastic carcinoma (66.6%) subgroups. PD-L1 expression of tumors was positively correlated with their Ki-67 score and PD-L1 positivity of the tumor microenvironment. No significant relationship was found between the other variables.

 

Conclusion: PD-L1 expression rate was remarkable both in the tumor and the tumor microenvironment of TNBCs. Larger cohorts of TNBC are required to further describe their PD-L1 expression characteristics and help standardize PD-L1 immunohistochemistry assays in these tumors.

 

Cite this article as: Doğukan R, Uçak R, Doğukan FM, Tanık C, Çitgez B, Kabukcuoğlu F. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. Eur J Breast Health 2019; 15(4): 235-241.

Key Words
Authors
All
Congresses
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Federation of Breast Diseases Associations | Latest Update: 01.10.2019